BRNS logo

BRNS

Profile

Full Name

Barinthus Biotherapeutics plc

Ticker Symbol

BRNS

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United Kingdom

IPO

April 30, 2021

Indexes

Not included

Website

http://www.barinthusbio.com

Employees

105

Key Details

Price

$0.70(-0.57%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$14.97M(+1766.46% YoY)

Annual EPS

-$1.55(+18.85% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.70
BRNS price is $0.70

30-Day Relative Volume

0.18
BRNS 30-day relative volume is 0.18

Price Performance

Price Most recent change

-0.57%
BRNS price was down -0.57% on Apr 14, 2025

Price YTD change

-42.14%
BRNS price is down -42.14% since January 1st

Price 1-year change

-73.54%
BRNS price is down -73.54% year-on-year

Price 3-year change

-88.48%
BRNS price is down -88.48% over the past 3 years

Price Range

Price All-time high

$17.99
BRNS price is currently -96.11% below its historical high of $17.99

Price 3-year low

$0.64
BRNS price is currently +9.22% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$28.20M
BRNS market capitalization is $28.20 million

Market cap 3-year change

-87.51%
BRNS market capitalization is down -87.51% over the past 3 years

Market cap All-time high

$579.09M
BRNS market capitalization is currently -95.13% below its historical high of $579.09 million

Market cap sector rank

31%
BRNS market capitalization is higher than 31% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+3.56%
BRNS shares outstanding is up +3.56% year-on-year

Shares Outstanding 3-Year Change

+8.46%
BRNS shares outstanding is up +8.46% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.39
BRNS beta is 0.39

200-day SMA

$1.16
BRNS price is currently -39.71% below its 200-day simple moving average

50-day SMA

$0.96
BRNS price is currently -26.94% below its 50-day simple moving average

RSI

30.77
BRNS 14-day relative strength index is 30.77

Volume

0.18
BRNS 30-day relative volume is 0.18

ATR

$0.09
BRNS average true range is $0.09

10-day Historical Volatility

104.01%
BRNS 10-day historical volatility is 104.01%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$14.97M
BRNS annual revenue is $14.97 million

Revenue Analysts estimate

-
BRNS annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

+1766.46%
BRNS annual revenue is up +1766.46% year-on-year

Revenue Sector rank

32.25%
BRNS annual revenue is higher than 32.25% of companies in Healthcare sector

EPS

EPS

-$1.55
BRNS annual earnings per share is -$1.55

EPS Analysts estimate

-$1.39
BRNS annual earnings per share is currently +11.25% higher than the consensus analysts' forecast

EPS 1-year change

+18.85%
BRNS annual earnings per share is up +18.85% year-on-year

EPS Sector rank

44.75%
BRNS annual earnings per share is higher than 44.75% of companies in Healthcare sector

Profit

Gross profit

-
BRNS annual gross profit value is unknown

Gross margin

-
BRNS annual gross profit margin value is unknown

Operating profit

-$51.78M
BRNS annual operating income is -$51.78 million

Operating margin

-345.90%
BRNS annual operating profit margin is -345.90%

Net income

-$61.07M
BRNS annual net profit is -$61.07 million

Net margin

-408.00%
BRNS annual net profit margin is -408.00%

Expenses

Total expenses

$66.75M
BRNS annual total expenses is $66.75 million

Operating expenses

$66.75M
BRNS annual total operating expenses is $66.75 million

Cost of goods sold

-
BRNS annual cost of goods sold value is unknown

Selling, general & administrative expenses

$29.67M
BRNS annual SGA is $29.67 million

Depreciation and amortization

$5.80M
BRNS annual depreciation & amortization is $5.80 million

Interest expense

$53.00K
BRNS annual interest expense is $53.00 thousand

Income tax

-$44.00K
BRNS annual income tax is -$44.00 thousand

EBIT & EBITDA

EBIT

-$61.17M
BRNS annual earnings before interest & taxes is -$61.17 million

EBITDA

-$55.37M
BRNS annual EBITDA is -$55.37 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$160.33M
BRNS annual total assets is $160.33 million

Non current assets

$34.59M
BRNS annual long term assets is $34.59 million

Current assets

$125.74M
BRNS annual total current assets is $125.74 million

Cash and cash equivalents

$110.66M
BRNS annual cash & cash equivalents is $110.66 million

Accounts receivable

-
BRNS annual accounts receivable value is unknown

Inventory

-
BRNS annual inventory value is unknown

Liabilities

Total liabilities

$30.19M
BRNS annual total liabilities is $30.19 million

Long term liabilities

$14.54M
BRNS annual total long term liabilities is $14.54 million

Current liabilities

$15.66M
BRNS annual total current liabilities is $15.66 million

Accounts payable

$2.47M
BRNS annual accounts payable is $2.47 million

Debt

Total debt

$12.01M
BRNS annual total debt is $12.01 million

Total debt 1-year change

-7.47%
BRNS annual total debt is down -7.47% year-on-year

Long term debt

$10.09M
BRNS annual long term debt is $10.09 million

Short term debt

$1.92M
BRNS annual short term debt is $1.92 million

Equity & Capital

Shareholders equity

$130.03M
BRNS annual stockholders equity is $130.03 million

Book value

$130.03M
BRNS annual book value is $130.03 million

Retained earnings

-$237.66M
BRNS annual retained earnings is -$237.66 million

Working capital

$110.08M
BRNS annual working capital is $110.08 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$28.94M
BRNS annual cash flow from operations is -$28.94 million

Cash from operations 1-year change

+43.17%
BRNS annual cash flow from operations is up +43.17% year-on-year

Cash from investing

-$892.00K
BRNS annual cash flow from investing activities is -$892.00 thousand

Cash from investing 1-year change

+83.52%
BRNS annual cash flow from investing activities is up +83.52% year-on-year

Cash from financing

$2.16M
BRNS annual cash flow from financing activities is $2.16 million

Cash from financing 1-year change

+15.54%
BRNS annual cash flow from financing activities is up +15.54% year-on-year

CAPEX

CAPEX

$892.00K
BRNS annual capital expenditures is $892.00 thousand

CAPEX 1-year change

-83.52%
BRNS annual capital expenditures is down -83.52% year-on-year

Free Cash Flow

Free cash flow

-$29.83M
BRNS annual free cash flow is -$29.83 million

Free cash flow 1-year change

+47.05%
BRNS annual free cash flow is up +47.05% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
BRNS annual gross profit margin value is unknown

Operating margin

-345.90%
BRNS annual operating profit margin is -345.90%

Net margin

-408.00%
BRNS annual net profit margin is -408.00%

ROA & ROE

ROA

-32.59%
BRNS annual return on assets is -32.59%

ROE

-38.52%
BRNS annual return on equity is -38.52%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
BRNS price to earnings ratio value is unknown

PE ratio Sector rank

-
BRNS price to earnings ratio is unknown

PB Ratio

PB ratio

0.22
BRNS price to book ratio is 0.22

PB ratio Sector rank

20.25%
BRNS price to book ratio is higher than 20.25% of companies in Healthcare sector

PS Ratio

PS ratio

-
BRNS price to sales ratio value is unknown

PS ratio Sector rank

-
BRNS price to sales ratio is unknown

Enterprise value

Enterprise value

-$70.46M
BRNS enterprise value is -$70.46 million

Enterprise value Sector rank

1.07%
BRNS enterprise value is higher than 1.07% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

1.27
BRNS EV/EBITDA is 1.27

EV/EBITDA Sector rank

75.22%
BRNS EV/EBITDA is higher than 75.22% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

8.03
BRNS annual current ratio is 8.03

Quick ratio

-
BRNS annual quick ratio value is unknown

Leverage

Debt to equity

0.00
BRNS annual debt to equity ratio is 0.00

Interest coverage ratio

-1154.23
BRNS annual interest coverage ratio is -1154.23

Risk & Stability

Piotroski F-Score

-
BRNS piotroski f-score value is unknown

Altman Z-Score

-1.86
BRNS altman z-score is -1.86

Analyst ratings

Recent major analysts updates

Mar 21, 25 HC Wainwright & Co.
Buy
Jan 13, 25 HC Wainwright & Co.
Buy
Nov 19, 24 HC Wainwright & Co.
Buy
Nov 8, 24 HC Wainwright & Co.
Buy
Oct 1, 24 HC Wainwright & Co.
Buy
Sep 26, 24 HC Wainwright & Co.
Buy
Aug 13, 24 Alliance Global Partners
Buy
Aug 12, 24 HC Wainwright & Co.
Buy
Jun 13, 24 Barclays
Overweight
Jun 7, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

ALGS logo
Aligos Therapeutics (ALGS)
CLGN logo
CollPlant Biotechnologies (CLGN)
GDTC logo
CytoMed Therapeutics Limited (GDTC)
OS Therapies Incorporated (OSTX)
INTS logo
Intensity Therapeutics (INTS)
DRIO logo
DarioHealth (DRIO)
Aspire BioPharma (ASBP)
BOLD logo
Boundless Bio (BOLD)
MLEC logo
Moolec Science SA (MLEC)
  • What is the ticker symbol for Barinthus Biotherapeutics?
  • Does Barinthus Biotherapeutics pay dividends?
  • What sector is Barinthus Biotherapeutics in?
  • What industry is Barinthus Biotherapeutics in?
  • What country is Barinthus Biotherapeutics based in?
  • When did Barinthus Biotherapeutics go public?
  • Is Barinthus Biotherapeutics in the S&P 500?
  • Is Barinthus Biotherapeutics in the NASDAQ 100?
  • Is Barinthus Biotherapeutics in the Dow Jones?
  • When was Barinthus Biotherapeutics's last earnings report?
  • When does Barinthus Biotherapeutics report earnings?
  • Should I buy Barinthus Biotherapeutics stock now?

What is the ticker symbol for Barinthus Biotherapeutics?

The ticker symbol for Barinthus Biotherapeutics is NASDAQ:BRNS

Does Barinthus Biotherapeutics pay dividends?

No, Barinthus Biotherapeutics does not pay dividends

What sector is Barinthus Biotherapeutics in?

Barinthus Biotherapeutics is in the Healthcare sector

What industry is Barinthus Biotherapeutics in?

Barinthus Biotherapeutics is in the Biotechnology industry

What country is Barinthus Biotherapeutics based in?

Barinthus Biotherapeutics is headquartered in United Kingdom

When did Barinthus Biotherapeutics go public?

Barinthus Biotherapeutics's initial public offering (IPO) was on April 30, 2021

Is Barinthus Biotherapeutics in the S&P 500?

No, Barinthus Biotherapeutics is not included in the S&P 500 index

Is Barinthus Biotherapeutics in the NASDAQ 100?

No, Barinthus Biotherapeutics is not included in the NASDAQ 100 index

Is Barinthus Biotherapeutics in the Dow Jones?

No, Barinthus Biotherapeutics is not included in the Dow Jones index

When was Barinthus Biotherapeutics's last earnings report?

Barinthus Biotherapeutics's most recent earnings report was on Mar 20, 2025

When does Barinthus Biotherapeutics report earnings?

The next expected earnings date for Barinthus Biotherapeutics is May 13, 2025

Should I buy Barinthus Biotherapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page